DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis – with future targets for further and new patient groups and segments.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Jeppe Krog Rasmussen | 9,10 | 9,10 | 2022-12-31 |
| Sellers of CannGros ApS | 7,85 | 7,85 | 2021-10-05 |
| Alexander Schoeneck | 6,21 | 6,21 | 2022-06-30 |
| Futur Pension | 5,56 | 5,56 | 2021-09-30 |
| Morten Martinsen | 1,41 | 1,41 | 2021-12-30 |
| Hansen & Nytoft Invest Aps | 1,34 | 1,34 | 2021-08-19 |
| Vavi Invest Aps | 0,88 | 0,88 | 2021-08-19 |
| John Frellsen | 0,60 | 0,60 | 2021-07-26 |
| JBJensen ApS | 0,53 | 0,53 | 2021-08-19 |
| Per Wester | 0,50 | 0,50 | 2021-08-19 |
2023-04-18 Årsstämma 2022
2023-05-31 Delårsrapport 2023-Q1
2023-08-31 Delårsrapport 2023-Q2
2023-11-30 Delårsrapport 2023-Q3